IRadimed Corporation
IRMD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $73,242 | $65,562 | $53,303 | $41,815 |
| % Growth | 11.7% | 23% | 27.5% | – |
| Cost of Goods Sold | $16,892 | $15,404 | $12,021 | $9,765 |
| Gross Profit | $56,350 | $50,158 | $41,282 | $32,050 |
| % Margin | 76.9% | 76.5% | 77.4% | 76.6% |
| R&D Expenses | $2,832 | $2,859 | $2,278 | $1,905 |
| G&A Expenses | $15,937 | $15,122 | $10,697 | $9,771 |
| SG&A Expenses | $31,554 | $27,264 | $23,377 | $20,327 |
| Sales & Mktg Exp. | $15,616 | $12,142 | $12,680 | $10,556 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $34,385 | $30,123 | $25,655 | $22,232 |
| Operating Income | $21,965 | $20,035 | $15,628 | $9,818 |
| % Margin | 30% | 30.6% | 29.3% | 23.5% |
| Other Income/Exp. Net | $2,311 | $1,703 | $553 | $19 |
| Pre-Tax Income | $24,275 | $21,738 | $16,181 | $9,836 |
| Tax Expense | $5,041 | $4,545 | $3,352 | $511 |
| Net Income | $19,234 | $17,193 | $12,828 | $9,325 |
| % Margin | 26.3% | 26.2% | 24.1% | 22.3% |
| EPS | 1.52 | 1.36 | 1.02 | 0.76 |
| % Growth | 11.8% | 33.3% | 34.2% | – |
| EPS Diluted | 1.5 | 1.35 | 1.02 | 0.74 |
| Weighted Avg Shares Out | 12,670 | 12,603 | 12,563 | 12,346 |
| Weighted Avg Shares Out Dil | 12,784 | 12,723 | 12,636 | 12,591 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2,193 | $1,864 | $582 | $35 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $818 | $765 | $671 | $1,407 |
| EBITDA | $22,782 | $20,801 | $16,298 | $11,225 |
| % Margin | 31.1% | 31.7% | 30.6% | 26.8% |